MA48791A - Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies - Google Patents
Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathiesInfo
- Publication number
- MA48791A MA48791A MA048791A MA48791A MA48791A MA 48791 A MA48791 A MA 48791A MA 048791 A MA048791 A MA 048791A MA 48791 A MA48791 A MA 48791A MA 48791 A MA48791 A MA 48791A
- Authority
- MA
- Morocco
- Prior art keywords
- praxipexole
- synucleinopathies
- zonisamide
- treatment
- related processes
- Prior art date
Links
- 208000032859 Synucleinopathies Diseases 0.000 title 1
- UBQNRHZMVUUOMG-UHFFFAOYSA-N zonisamide Chemical compound C1=CC=C2C(CS(=O)(=O)N)=NOC2=C1 UBQNRHZMVUUOMG-UHFFFAOYSA-N 0.000 title 1
- 229960002911 zonisamide Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762511424P | 2017-05-26 | 2017-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA48791A true MA48791A (fr) | 2020-04-08 |
Family
ID=64397000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA048791A MA48791A (fr) | 2017-05-26 | 2018-05-23 | Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20200138792A1 (fr) |
| EP (1) | EP3630289A4 (fr) |
| AU (1) | AU2018271895A1 (fr) |
| CA (1) | CA3099090A1 (fr) |
| MA (1) | MA48791A (fr) |
| TW (1) | TW201900163A (fr) |
| WO (1) | WO2018217845A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007652A (es) * | 2018-12-27 | 2021-08-05 | Chase Therapeutics Corp | Combinaciones y uso de antineurodegenerativos de domperidona. |
| TWI870475B (zh) * | 2019-10-02 | 2025-01-21 | 美商卡凡恩公司 | 用於治療神經毒性之方法及材料 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030032661A1 (en) * | 2001-08-02 | 2003-02-13 | Boehringer Ingelheim Pharma Kg | Pramipexole as an anticonvulsant |
| WO2008010768A1 (fr) * | 2006-07-17 | 2008-01-24 | Cereuscience Ab | Méthode de traitement et de diagnostic du syndrome des jambes sans repos et de mouvements involontaires des membres pendant le sommeil et moyen pour la mise en oeuvre de ladite méthode |
| WO2009054543A1 (fr) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Antagonistes du récepteur ampa et zonisamide destinés à traiter la maladie de parkinson et les troubles moteurs |
| WO2009133128A1 (fr) * | 2008-04-29 | 2009-11-05 | Pharnext | Compositions combinées destinées à traiter la maladie d’alzheimer et les troubles associés, au moyen de zonisamide et d’acamprosate |
| WO2010010138A1 (fr) * | 2008-07-24 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique renfermant du pramipexole et un inhibiteur des canaux calciques pour le traitement de la maladie de parkinson |
-
2018
- 2018-05-23 AU AU2018271895A patent/AU2018271895A1/en not_active Abandoned
- 2018-05-23 CA CA3099090A patent/CA3099090A1/fr not_active Abandoned
- 2018-05-23 WO PCT/US2018/034050 patent/WO2018217845A1/fr not_active Ceased
- 2018-05-23 US US16/612,805 patent/US20200138792A1/en not_active Abandoned
- 2018-05-23 MA MA048791A patent/MA48791A/fr unknown
- 2018-05-23 EP EP18805392.0A patent/EP3630289A4/fr not_active Withdrawn
- 2018-05-25 TW TW107117886A patent/TW201900163A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3630289A1 (fr) | 2020-04-08 |
| CA3099090A1 (fr) | 2018-11-29 |
| TW201900163A (zh) | 2019-01-01 |
| US20200138792A1 (en) | 2020-05-07 |
| WO2018217845A1 (fr) | 2018-11-29 |
| EP3630289A4 (fr) | 2021-03-03 |
| AU2018271895A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| EP3436002A4 (fr) | Combinaisons pharmaceutiques pour le traitement du cancer | |
| EP3431105A4 (fr) | Composition médicinale pour le traitement du cancer | |
| EP3374502A4 (fr) | Procédés pour le traitement de dystrophies cornéennes | |
| MA49144A (fr) | Polythérapies pour le traitement du cancer | |
| MA71705A (fr) | Substances et procédés pour le traitement d'hémoglobinopathies | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| EP3481387A4 (fr) | Methodes et compositions pour le traitement de troubles épileptiques | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| MA42439A (fr) | Agents, utilisations et procédés pour le traitement d'une synucléinopathie | |
| EP3533466A4 (fr) | Composition pharmaceutique pour le traitement et/ou la prévention du cancer | |
| EP3635130A4 (fr) | Médicament de précision pour le traitement et la prévention du risque suicidaire | |
| MA50409A (fr) | Polythérapies pour le traitement du cancer | |
| EP3504187A4 (fr) | Utilisation de la pridopidine pour le traitement du déclin fonctionnel | |
| MA48637A (fr) | Polythérapies pour le traitement du cancer | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| EP3474854A4 (fr) | Associations médicamenteuses pour le traitement du cancer | |
| EP3630196A4 (fr) | Polythérapies pour le traitement de cancers | |
| EP3766497A4 (fr) | Médicament pour le traitement de la toux | |
| MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
| MA43825A (fr) | Schémas posologiques pour le traitement d'infections fongiques | |
| MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
| EP3579837C0 (fr) | Axitinib, nintedanib ou lenvatinib pour le traitement de la rosacée et de la dermatite atopique | |
| EP3426254A4 (fr) | Utilisation d'inhibiteurs de braf pour le traitement de réactions cutanées | |
| EP3365014A4 (fr) | Méthodes et compositions pour le traitement de la mastocytose systémique |